title: Antisense inhibition of membrane-bound human interleukin-5 receptor-alpha chain does not affect soluble receptor expression and induces apoptosis in TF-1 cells.
abstract: Binding of human interleukin-5 (HuIL-5) to its membrane-anchored receptor (IL-5R) triggers multiple signaling pathways, cellular proliferation, and maturational responses, as well as protection from apoptosis. In contrast, soluble forms of the HuIL-5R have been shown to inhibit IL-5 signaling and, therefore, may represent naturally occurring negative regulators of IL-5 function. Because of the central role of IL-5 in promoting eosinophilia and airway hyperresponsiveness in animal models of asthma, antisense oligonucleotides specific either for the membrane form alone or for sequences shared between both the membrane and soluble forms of the HuIL-5Ralpha ligand binding chain were designed. The activities of these oligonucleotides were characterized in IL-5R-expressing erythroleukemic TF-1 cells. Herein we report that an antisense oligonucleotide targeted to a sequence unique to the alternatively spliced membrane-bound form of the HuIL-5Ralpha chain has been developed that selectively inhibits membrane, but not soluble, mRNA isoform expression. Both this membrane-specific oligonucleotide and an antisense oligonucleotide targeted to sequence common to both membrane and soluble isoforms were found to potently suppress cell surface IL-5Ralpha levels and IL-5-mediated cell survival by inducing apoptosis similar to IL-5 withdrawal. Thus, these oligonucleotides represent unique genetic agents with therapeutic potential for diseases with an eosinophilic component.
authors.affiliation: Department of Molecular and Cellular Pharmacology, Isis Pharmaceuticals, Carlsbad, CA 92008, USA.
authors.forename: J G
authors.initials: JG
authors.lastname: Karras
authors.forename: R A
authors.initials: RA
authors.lastname: McKay
authors.forename: T
authors.initials: T
authors.lastname: Lu
authors.forename: N M
authors.initials: NM
authors.lastname: Dean
authors.forename: B P
authors.initials: BP
authors.lastname: Monia
mesh_terms: D017398:Alternative Splicing / Q000235:genetics; D017209:Apoptosis / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005434:Flow Cytometry; D006801:Humans; D015848:Interleukin-5 / Q000494:pharmacology; D007700:Kinetics; D004915:Leukemia, Erythroblastic, Acute / Q000235:genetics / Q000378:metabolism; D008565:Membrane Proteins / Q000096:biosynthesis* / Q000235:genetics / Q000378:metabolism; D016376:Oligonucleotides, Antisense / Q000235:genetics*; D010766:Phosphorylation; D020033:Protein Isoforms / Q000235:genetics; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D018123:Receptors, Interleukin / Q000096:biosynthesis / Q000235:genetics* / Q000378:metabolism*; D053649:Receptors, Interleukin-5; D015398:Signal Transduction / Q000187:drug effects; D012995:Solubility; D013379:Substrate Specificity; D014162:Transfection; D014407:Tumor Cells, Cultured
chemical_list: D015848:Interleukin-5; D008565:Membrane Proteins; D016376:Oligonucleotides, Antisense; D020033:Protein Isoforms; D012333:RNA, Messenger; D018123:Receptors, Interleukin; D053649:Receptors, Interleukin-5